Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27781245 | 1.00 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL4178088 | 0.93 | PIK3CD (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL27781229 | 0.93 | PIK3CD (0.66) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL12005581 | 0.92 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL4172105 | 0.90 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL27781353 | 0.90 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL1884069 | 0.90 | PIK3CG (0.75) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL12004769 | 0.88 | PIK3CD (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL27781290 | 0.88 | PIK3CD (0.58) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL12004278 | 0.87 | PIK3CD (0.64) | PIK3CGPIK3CDPIK3CAPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| CN-101715453-B | Heterocyclic compounds and their uses | AMGEN INC | 2012-06-27 | — | — | CN | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CG 54/4885PIK3CD 16/4885PIK3CA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.